Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.

Author(s): Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE

Affiliation(s): Department of Paediatrics, Umea University, Umea, Sweden. anders.erikson.us@vll.se

Publication date & source: 2006-03, Acta Paediatr., 95(3):312-7.

Publication type:

AIM: To study the long-term effects of enzyme replacement therapy on the neurological signs of chronic neuronopathic Gaucher disease and to evaluate some biochemical parameters for monitoring the treatment. METHODS: Eight patients from the Norrbottnian cohort were followed during 10 y of treatment. They were followed with regular clinical observations, biochemical tests and psychometric testing. RESULTS: After the start of treatment, their general well-being improved and was stable during the follow-up. In three of the patients there were some indications of slow neurological deterioration. The mean results of psychometric testing did not decrease. Glucosylceramide and chitotriosidase levels were useful in monitoring the treatment. The chemokine CCL18 also seems to be a useful parameter for future monitoring. CONCLUSIONS: Enzyme replacement therapy seems to slow down further neurological and mental deterioration in mild chronic neuronopathic (type 3) Gaucher disease.